

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **VOLUNTARY ANNOUNCEMENT**

### **FIRST PATIENT DOSED IN THE PHASE I CLINICAL TRIAL OF IMC-003/IMM72**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**,” together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that the first patient has been successfully dosed in the Phase I clinical trial of IMC-003/IMM72. This marks a milestone achievement in the Group’s clinical research of IMC-003/IMM72 and laying a solid foundation for the advancement of subsequent clinical trials.

### **ABOUT IMC-003/IMM72**

IMC-003/IMM72 is a new generation activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein through genetic engineering modification with improved activity and quality attributes. The Group owns the global intellectual property rights and development and commercialization rights of IMC-003/IMM72.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMC-003/IMM72, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, August 18, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*